Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Paats, I. Bergen, W. Hanselaar, C. Groeninx van Zoelen, H. Hoogsteden, R. Hendriks, M. van der Eerden (Rotterdam, Netherlands). Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia. Eur Respir J 2012; 40: Suppl. 56, 2542

Member's Comments

No comment yet.

Related content which might interest you: Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia Source: Eur Respir J 2013; 41: 1378-1385 Year: 2013 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Systemic cytokine levels in community-acquired pneumonia and their association with disease severity Source: Eur Respir J 2002; 20: 990-995 Year: 2002 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Systemic cytokine response in patients with community-acquired pneumonia Source: Eur Respir J 2011; 37: 1431-1438 Year: 2011 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 The clinical significance of serum and bronchoalveoalr lavage inflammatory cytokine in patients with acute respiratory failure due to severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 347s Year: 2006 Evolution of cytokines/chemokines in cases with severe nosocomial pneumonia and distinct etiologies in mechanical ventilated patients. Source: Virtual Congress 2021 – Acute paediatric respiratory infections Year: 2021 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 is hypercapnia associated with severe forms of community-acquired pneumonia? Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007